先健科技(01302.HK)成立聯合實驗室加速開展大麻素科研工作
先健科技(01302.HK)公布,9月16日公司達成合作協議,透過深圳云麻與中國科學院深圳先進技術研究院腦認知與腦疾病研究所共同成立了聯合實驗室加速開展大麻素干預腦疾病作用的相關科研工作,重點佈局水溶性CBD在癲癇病、自閉症、恐懼症、帕金森病、睡眠障礙癥等認知障礙性疾病的相關科學研究,並為未來的商業化安排積累數據。同時,雙方將依託各自優勢共同為聯合實驗室申請各級政府的科技資助項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.